

CONTENT

	Page No.
ABBREVIATIONS	viii-xii
1. INTRODUCTION	1-11
2. REVIEW OF LITERATURE	12-54
2.1 Epidemiology	12
2.1.1 Global epidemiology of neonatal mortality and morbidity due to sepsis	12
2.1.2 Epidemiology of neonatal mortality and morbidity in India due to sepsis	13
2.2 Classification of neonatal sepsis	14
2.2.1 Early onset sepsis (EOS)	14
2.2.2 Late onset sepsis (LOS)	14
2.3 Etiologic agents	15-17
2.4 Risk Factors	17
2.4.1 Intrinsic risk factors	18
2.4.1.1 Neonatal factors	18
2.4.1.2 Maternal factors	18
2.4.2 Extrinsic risk factors	18-19
2.4.3 Environmental risk factors	19-20
2.5 Clinical Manifestations	20-21
2.6 Diagnosis	21
2.6.1 Blood culture	21
2.6.2 Urine culture	22
2.6.3 Haematological markers	22
2.6.4 Biomarkers	22
2.6.4.1 C-reactive protein (CRP)	22-23
2.6.4.2 Procalcitonin (PCT)	23
2.6.4.3 Serum Amyloid A (SAA)	24
2.6.4.4 Liposaccharide binding protein (LBP)	24

2.6.4.5 Cytokines	24-25
2.6.4.6 Cell surface markers	25-26
2.7 Prevention	26
2.7.1 Before Delivery	26
2.7.2 During Delivery	26-27
2.7.3 After Delivery	27
2.8 Treatment	27-28
2.9 <i>E. coli</i> in neonatal sepsis	28-30
2.9.1 Clinical categories of <i>E. coli</i>	30
2.9.1.1 Commensal <i>E. coli</i>	30-31
2.9.1.2 Intestinal Pathogenic <i>E. coli</i> (IPEC)	31
2.9.1.3 Extraintestinal Pathogenic <i>E. coli</i> (ExPEC)	31-33
2.9.2 Phylogrouping of <i>E. coli</i>	33
2.9.3 Virulence factors (VFs) of septicemic <i>E. coli</i>	33
2.9.3.1 Iron acquisition system	33-35
2.9.3.2 Secreted toxins	35-37
2.9.3.3 Adhesins	37-39
2.9.3.4 Secretion systems	39
2.9.3.5 Serum resistance	40
2.9.3.6 Genes involved in internalization in host cells	40
2.10 Serine Protease Autotransporters of <i>Enterobacteriaceae</i> (SPATEs)	40-41
2.10.1 Structure of SPATEs	41-42
2.10.2 Classification of SPATEs	42-43
2.10.3 Mechanism of secretion	43-45
2.10.4 Role of SPATEs in pathogenesis	45
2.10.4.1 Class I SPATEs	46
2.10.4.1.1 EspP	46
2.10.4.1.2 EspC	46-47
2.10.4.1.3 Pet	47
2.10.4.1.4 SigA	48
2.10.4.1.5 Sat	48-49
2.10.4.2 Class II SPATEs	49
2.10.4.2.1 Vat	49

2.10.4.2.2 Tsh	49-50
2.10.4.2.3 Hbp	50
2.10.4.2.4 Pic	50-51
2.10.4.2.5 SepA	51
2.10.4.2.6 EatA	51-52
2.11 <i>E. coli</i> metalloprotease YghJ	52-54
3. OBJECTIVES	55
4. MATERIALS AND METHODS	56-86
4.1 Reagents	56-57
4.2 Bacterial strains	57-59
4.3 Animals	59
4.4 Plasmid and oligonucleotides	59-60
4.5 Triplex PCR for phylogrouping	60-61
4.6 PCR for profiling of virulence genes	61-62
4.7 PCR for identification of SPATEs	62
4.8 Agarose gel electrophoresis	63
4.8.1 Preparation of reagents	63
4.8.2 Procedure	63
4.9 DNA Sequencing	63-65
4.10 Pulsed field gel electrophoresis (PFGE)	65
4.10.1 Preparation of reagents	65
4.10.2 Procedure	65-66
4.11 Animal model using suckling mice	66-68
4.12 Protease activity assay	68
4.12.1 Skim milk assay (SMA)	68
4.12.2 Azocasein assay	68
4.12.2.1 Preparation of reagents	68
4.12.2.2 Procedure	68-69
4.12.3 Oligopeptide substrate assay	69
4.12.4 Gelatin zymography	69
4.12.4.1 Preparation of reagents	69-70

4.12.4.2 Procedure	70
4.13 Partial purification of YghJ	70
4.13.1 Concentration of proteins	70
4.13.2 Estimation of protein concentration	70-71
4.13.3 Anion-exchange chromatography	71
4.13.4 Gel filtration chromatography	71
4.13.5 SDS-PAGE	72
4.13.5.1 Preparation of reagents	72
4.13.5.2 Preparation of resolving and stacking gels	72
4.13.5.3 Electrophoresis buffer	72
4.13.5.4 Preparation of sample buffer	72
4.13.5.5 Preparation of sample	73
4.13.5.6 Electrophoresis	73
4.13.5.7 Fixing, staining and destaining of gel	73
4.13.6 NATIVE-PAGE	73
4.14 Identification of protein by MS/MS peptide mapping	73
4.14.1 In Gel Trypsin digestion of proteins	74
4.14.1.1 Preparation of reagents	74
4.14.1.2 Procedure	74-75
4.15 Raising of antisera against YghJ	75
4.16 Cloning, expression and purification of YghJ	75
4.16.1 Isolation of genomic DNA using CTAB	75
4.16.1.1 Preparation of reagents	75
4.16.1.2 Procedure	75-76
4.16.2 Quantification of DNA and analysis of purity	76
4.16.3 PCR amplification of <i>yghJ</i> for cloning	76
4.16.4 Cloning of <i>yghJ</i> into pBAD TOPO expression vector	76-77
4.16.5 Preparation of competent cells	77-78
4.16.6 Transformation	78
4.16.7 Plasmid DNA isolation	78
4.16.8 PCR screening for confirmation of positive clone	78
4.16.9 Expression of cloned YghJ	79
4.16.10 Immunoblotting	79

4.16.10.1	Preparation of reagents	79-80
4.16.10.2	Procedure	80
4.16.11	Purification of rYghJ through Ni-NTA chromatography	80
4.16.11.1	Preparation of reagents	80
4.16.11.2	Procedure	81
4.16.12	Purification through Gel-filtration chromatography	81
4.17	PCR to study distribution of YghJ	81
4.18	TCA precipitation of proteins	82
4.19	Inhibition of protease activity	82
4.20	Determination of optimum pH for protease activity	82
4.21	Determination of optimum temperature for protease activity	83
4.22	Cell culture and treatment	83-84
4.23	Determination of cytokines production by ELISA	84-85
4.24	RNA extraction using TRIzol	85
4.25	Quantification of RNA and analysis of purity	85
4.26	Preparation of cDNA	86
4.27	Reverse Transcription (RT) PCR	86
4.28	Statistical analysis	86
5.	RESULTS PART - A	87-102
5.1	Host clinical characteristics	87-88
5.2	Phylogenetic distribution of <i>E. coli</i> isolates	87,89-90
5.3	Phylogenetic distribution of virulence factors (VFs) among septicemic, fecal and environmental <i>E. coli</i> isolates	90-92
5.4	Phylogenetic distribution of SPATE and its subtypes among septicemic, fecal and environmental <i>E. coli</i> isolates	92-95
5.5	Distribution of class I and class II SPATEs among septicemic isolates	96
5.6	Comparison of occurrence of SPATEs among septicemic, fecal and environmental <i>E. coli</i> isolates	96-97
5.7	Comparison of occurrence of SPATEs and VFs among Different phylogroups of septicemic and fecal isolates	97-98
5.8	Phenotypic expression of SPATEs by skim milk assay (SMA)	98

5.9	Determination of clonality of septicemic isolates	99-100
5.10	Lethality of septicemic isolates possessing SPATEs but lacking the tested VFs in neonatal mice model	101-102
	RESULTS PART- B	103-124
5.11	Partial purification and identification of YghJ from NSEC strain EB260	103
5.11.1	Detection of secreted protease activity from EB260	103
5.11.1.1	AAPM pNA Oligopeptide substrate assay	103
5.11.1.2	Gelatin zymography	103
5.11.1.3	Azocasein assay	104
5.11.2	Partial purification of the secreted protease	104-106
5.11.3	Protein identification by MS/MS peptide mapping	106-109
5.12	Cloning, expression and purification of YghJ	109
5.12.1	Molecular cloning of YghJ	109
5.12.1.1	PCR amplification of YghJ	109
5.12.1.2	Cloning and confirmation of clone	110
5.12.2	Expression of rYghJ	110
5.12.2.1	Induction with L-arabinose and SDS-PAGE analysis	110-111
5.12.2.2	Confirmation of rYghJ expression by Immunoblot	111
5.12.3	Purification of rYghJ from TOP10 <i>E. coli</i> cells	112
5.12.3.1	Ni-NTA column chromatography	112
5.12.3.2	Gel filtration chromatography	112-113
5.13	Characterization of rYghJ	114
5.13.1	Effect of inhibitors on protease activity	114
5.13.2	Effect of pH on protease activity	114-115
5.13.3	Effect of temperature on protease activity	115
5.14	Distribution of YghJ among neonatal septicemic and fecal <i>E. coli</i> isolates	116
5.14.1	Genotypic distribution of YghJ among different phylogroups of septicemic and fecal <i>E. coli</i> isolates	116-117

5.14.2 Phenotypic distribution of YghJ	117-118
5.14.3 Determination of association of SPATEs with YghJ	118
5.15 Role of YghJ in pathogenesis of NSEC isolate	118
5.15.1 Cytotoxic effect of Yghj on human intestinal epithelial cell lines	118-119
5.15.2 Induction of proinflammatory cytokines by YghJ	120-124
6. DISCUSSION	125-139
7. SUMMARY	140-142
8. REFERENCES	143-171
9. PUBLICATIONS	172